953. Vaccine waning and mumps re-emergence in the United States
Session: Oral Abstract Session: Public Health Potpourri
Friday, October 6, 2017: 9:15 AM
Room: 07AB

Background: Following decades of declining mumps incidence amid widespread vaccination, the US has experienced a resurgence in mumps cases since 2006 driven largely by outbreaks on college campuses. The occurrence of cases among previously-vaccinated individuals and in communities with high vaccine coverage has prompted concerns about performance of the live attenuated mumps vaccine (Jeryl Lynn strain) currently included in the measles-mumps-rubella (MMR) series. It is unclear whether the resurgence is due to antigenic changes in circulating mumps virus, which would warrant consideration of a new vaccine, or to waning vaccine-derived protection, necessitating additional booster doses.

Methods: We pooled data from studies of vaccine effectiveness to test for waning of protection. We used mathematical models to measure changes in population immunity since mumps vaccine introduction and to assess whether recent mumps transmission dynamics are consistent with hypotheses of waning immunity or vaccine escape.

Results: We estimate that vaccine-derived protection persists, on average, 29 (95%CI: 17-54) years after receipt of the last dose (Figure 1). This waning accounts for 66.4% of unexplained variation in estimates of mumps vaccine effectiveness across published studies. Changes in age-specific susceptibility due to vaccine waning and declining transmission track with the current resurgence in cases among young adults in the US, and explain outbreaks reported among vaccinated adolescents during the late 1980s (Figure 2). In contrast, vaccine escape would not be expected to result in cases following the observed age distribution (Figure 3). Routine adult booster vaccination is needed to sustain mumps elimination.

Conclusion: The resurgence of mumps in the United States since 2006 is attributable to waning of vaccine-derived immunity, suggesting the need for booster doses in adulthood. Trials are needed to assess clinical protection afforded by booster doses in individuals with a history of MMR vaccination.

Joseph Lewnard, PhD, Center for Communicable Disease Dynamics, Harvard TH Chan School of Public Health, Boston, MA and Yonatan H. Grad, MD, PhD, Immunology & Infectious Diseases (HSPH) and Division of Infectious Diseases (BWH), Harvard T.H. Chan School of Public Health and Brigham & Women's Hospital, Harvard Medical School, Boston, MA

Disclosures:

J. Lewnard, Pfier: Grant Investigator , Research grant

Y. H. Grad, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.